Patient Perspectives on Switching from Infliximab to Infliximab‐dyyb in Patients with Rheumatologic Diseases in the United States-Reference-Cited by-同舟云学术

Patient Perspectives on Switching from Infliximab to Infliximab‐dyyb in Patients with Rheumatologic Diseases in the United States

Published:2019-03 Issue:1 Volume:1 Page:52-57
ISSN:2578-5745
Container-title:ACR Open Rheumatology
language:en
Short-container-title:ACR Open Rheumatology

Author:

Chau Jason¹,Delate Thomas²^ORCID,Ota Taylor²,Bhardwaja Bharati³

Affiliation:

1. Kaiser Permanente Washington Tacoma Washington

2. Kaiser Permanente Colorado, Aurora, Colorado, and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus Aurora Colorado

3. Kaiser Permanente Colorado Aurora Colorado

Funder

Kaiser Permanente

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.1007

Reference18 articles.

1. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability

2. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues;Lapadula G;Clin Exp Rheumatol,2012

4. U.S. Food and Drug Administration.Prescribing biosimilar and interchangeable products.2017. URL:https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580430.htm.

5. Inflectra – an infliximab biosimilar;The Medical Letter;Med Lett Drugs Ther,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review;BioDrugs;2024-06-15

2. Knowledge of medications and understanding of Mexican patients regarding the non-medical switch from originator to its biosimilar in inflammatory arthritis;Revista Colombiana de Reumatología;2024-03

3. Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto;Clinical Rheumatology;2023-11-21

4. Patients’ Perceptions of Biosimilars: A Systematic Review;BioDrugs;2023-09-07

5. Perspectives on Nonmedical Switching and the COVID-19 Pandemic: A Narrative Review;The American Journal of Managed Care;2022-09-26